New therapeutic approaches in Alzheimer's disease;Nouvelles approches thérapeutiques dans la Maladie d'Alzheimer

Encephale

Volumn 32, Issue 4 V, 2006, Pages

  Augy, T ^a   Bonin Guillaume, S ^b,c   Blin, O ^c  

^a HÔPITAL DE LA CONCEPTION   (France)

^b HÔPITAL NORD   (France)

^c TIMONE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SECRETASE; ALPHA TOCOPHEROL; ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN[1-42]; AMYLOID PROTEIN; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; ATORVASTATIN; BETA SECRETASE; CHOLINESTERASE INHIBITOR; CLIOQUINOL; DONEPEZIL; ENZYME INHIBITOR; ESTROGEN; GALANTAMINE; GAMMA SECRETASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; INSULIN; MEMANTINE; PLACEBO; RIVASTIGMINE; ROFECOXIB; SELEGILINE; SIMVASTATIN; TACRINE;

ALZHEIMER DISEASE; BIOACCUMULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHROMOSOME 14Q; CHROMOSOME 21Q; CHROMOSOME ABERRATION; CLINICAL TRIAL; COGNITIVE DEFECT; DRUG INDICATION; DRUG TOLERABILITY; ESTROGEN THERAPY; GENE MUTATION; GENOTYPE ENVIRONMENT INTERACTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; MINI MENTAL STATE EXAMINATION; NEUROPATHOLOGY; PALLIATIVE THERAPY; PREVENTIVE MEDICINE; REVIEW; RISK REDUCTION; TREATMENT INDICATION; TREATMENT OUTCOME; VACCINATION;

AGED; ALZHEIMER DISEASE; BRAIN; CHROMOSOME MAPPING; CROSS-SECTIONAL STUDIES; DNA MUTATIONAL ANALYSIS; GENE THERAPY; HUMANS; NOOTROPIC AGENTS; PLAQUE, AMYLOID; POPULATION DYNAMICS; PROGNOSIS; SENILE PLAQUES;

EID: 33748412865     PISSN: 00137006     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (84)

1. AISEN PS, SCHAFER KA, GRUNDMAN M et al. Alzheimer's Disease Cooperative Study. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression : a randomized controlled trial. JAMA 2003 ; 289 (21) : 2819-26.
2. BASKIN F, ROSENBERG RN, DAVIS RM. Morphological differentiation and proteoglycan synthesis regulate Alzheimer amyloid precursor protein processing in PC-12 and human astrocyte cultures. J Neurosci Res 1992 ; 32 (2) : 274-9.
3. BASKIN F, ROSENBERG RN, FANG X et al. Correlation of statin-increased platelet APP ratios and reduced blood lipids in AD patients. Neurology 2003 ; 60 (12) : 2006-7.
4. BAYER AJ, BULLOCK R, JONES RW et al. Evaluation of the safety and immunogenicity of synthetic Abeta42 (AN1792) in patients with AD. Neurology 2005 ; 64 (1) : 94-101.
5. BECKMAN M. Untangling Alzheimer's by paring plaques bolsters amyloid theory. Science 2004 ; 305 : 762.
6. BEFFERT U, ARGUIN C, POIRIER J. The polymorphism in exon 3 of the low density lipoprotein receptor-related protein gene is weakly associated with Alzheimer's disease. Neurosci Lett 1999 ; 259 (1) : 29-32.
7. BENNETT DA, HOLTZMAN DM. Immunization therapy for Alzheimer disease ? Neurology 2005 ; 64 (1) : 10-2.
8. BIRKS J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev, 2006.
9. BIRD TD, LAMPE TH, NEMENS EJ et al. Familial Alzheimer's disease in American descendants of the Volga Germans : probable genetic founder effect. Ann Neurol. 1988 ; 23 (1) : 25-31.
10. BONIN-GUILLAUME S, ZEKRY D, GIACOBINI E et al. Impacts économiques de la démence. La Presse Médicale, 2005 ; 34 (1) : 35-41.
11. CACABELOS R. The application of functional genomics to Alzheimer's disease. Pharmacogenomics 2003 ; 4 (5) : 597-621.
12. COLLINS R, ARMITAGE J. High-risk elderly patients Prosper from cholesterol-lowering therapy. Lancet 2002 ; 360 (9346) : 1618-9.
13. CORDER EH, SAUNDERS AM, STRITTMATTER WJ et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993 ; 261 (5123) : 921-3.
14. COURTNEY C, FARRELL D, GRAY R et al. Long-term donépézil treatment in 565 patients with Alzheimer's disease (AD2000) : randomised double-blind trial. Lancet 2004 ; 363 (9427) : 2105-15.
15. CRAIG D, BIRKS J. Galantamine for vascular cognitive impairment. Cochrane Database Syst Rev 2006 ; (1) : CD004746.
16. CUMMINGS JL. Alzheimer's disease. N Engl J Med 2004 ; 351 (1) : 56-67.
17. DICKSON DW, LEE SC, MATTIACE LA et al. Microglia and cytokines in neurological disease, with special reference to AIDS and Alzheimer's disease. Glia 1993 ; 7 (1) : 75-83.
18. EMRE M, AARSLAND D, ALBANESE A et al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 2004 ; 351 (24) : 2509-18.
19. ESPELAND MA, RAPP SR, SHUMAKER SA et al. Women's Health Initiative Memory Study. Conjugated equine estrogens and global cognitive function in postmenopausal women : Women's Health Initiative Memory Study. JAMA 2004 ; 291 (24) : 2959-68.
20. FOLSTEIN MF, FOLSTEIN ME, McHUGH PR. «Mini-mental state». A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975 ; 12 : 189-98.
21. GAMES D, ADAMS D, ALESSANDRINI R et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature 1995 ; 373 (6514) : 523-7.
22. GEULA C, WU CK, SAROFF D et al. Aging renders the brain vulnerable to amyloid beta-protein neurotoxicity. Nat Med 1998 ; 4 (7) : 827-31.
23. GIACOBINI E. Cholinesterase inhibitors : new roles and therapeutic alternatives. Pharmacol Res 2004 ; 50 (4) : 433-40.
24. GLENNER GG, WONG CW. Alzheimer's disease and Down's syndrome : sharing of a unique cerebrovascular amyloid fibril protein. Biochem Biophys Res Commun 1984 ; 122 (3) : 1131-5.
25. GOATE A, CHARTIER-HARLIN MC, MULLAN M et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 1991 ; 349 (6311) : 704-6.
26. GOLDGABER D, LERMAN MI, McBRIDE OW et al. Characterization and chromosomal localization of a cDNA encoding brain amyloid of Alzheimer's disease. Science 1987 ; 235 (4791) : 877-80.
27. GRIFFIN WS, SHENG JG, ROYSTON MC et al. Glial-neuronal interactions in Alzheimer's disease : the potential role of a 'cytokine cycle' in disease progression. Brain Pathol 1998 ; 8 (1) : 65-72.
28. HEART PROTECTION STUDY COLLABORATIVE GROUP. MRC/BHF Heart Protection Study of cholestérol lowering with simvastatin in 20,506 high - risk individuals : a randomised placebo-controlled trial. Lancet 2002 ; 360 : 7-22.
29. HEBERT S. Analyse structurale et fonctionnelle de la présé niline I humaine : implications dans la maladie d'Alzheimer. Thèse de Sciences, Université de Laval, 2003.
30. HOCK C, KONIETZKO U, PAPASSOTIROPOULOS A et al. Generation of antibodies specific for beta-amyloid by vaccination of patients with Alzheimer disease. Nat Med 2002 ; 8 (11) : 1270-5.
31. HOCK C, KONIETZKO U, STREFFER JR et al. Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron 2003 ; 38 (4) : 547-54.
32. HOGLUND K, WIKLUND O, VANDERSTICHELE H et al. Plasma levels of beta-amyloid (1-40), beta-amyloid (1-42), and total beta-amyloid remain unaffected in adult patients with hypercholesterolemia after treatment with statins. Arch Neurol 2004 ; 61 (3) : 333-7.
33. HOLMES C, WILKINSON D, DEAN C et al. The efficacy of donépé zil in the treatment of neuropsychiatric symptoms in Alzheimer disease. Neurology 2004 ; 63 (2) : 214-9.
34. HOLTZMAN DM, BALES KR, TENKOVA T et al. Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 2000 ; 97 (6) : 2892-7.
35. JELIC V, KIVIPELTOM, WINBLAD B. Clinical trials in mild cognitive impairment : lessons for the future. J Neurol Neurosurg Psychiatry 2006 ; 77 (4) : 429-38.
36. JICK H, ZORNBERG GL, JICK SS et al. Statins and the risk of dementia. Lancet. 2000 ; 356 (9242) : 1627-31. Erratum. In : Lancet 2001 ; 357 (9255) : 562.
37. JIN YP, GATZ M, JOHANSSON B et al. Sensitivity and specificity of dementia coding in two Swedish disease registries. Neurology 2004 ; 63 (4) : 739-41.
38. KING HC, SINHA AA. Gene expression profile analysis by DNA microarrays : promise and pitfalls. JAMA 2001 ; 286 (18) : 2280-8.
39. KOWALL NW, BEAL MF, BUSCIGLIO J et al. An in vivo model for the neurodegenerative effects of beta amyloid and protection by substance P. Proc Natl Acad Sci USA 1991 ; 88 (16) : 7247-51.
40. LEWIS J, DICKSON DW, LIN WL et al. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 2001 ; 293 (5534) : 1487-91.
41. LIOTTA LA, KOHN EC, PETRICOIN EF. Clinical proteomics : personalized molecular medicine. JAMA 2001 ; 86 : 2211-4.
42. LOVEMAN E, GREEN C, KIRBY J et al. The clinical and cost-effectiveness of donépézil, rivastigmine, galantamine and memantine for Alzheimer's disease. Health Technol Assess 2006 ; 10 : 1-160.
43. MARKESBERY WR. The role of oxidative stress in Alzheimer disease. Arch Neurol 1999 ; 56 : 1449-52.
44. MASLIAH E, HANSEN L, ADAME A et al. Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology 2005 ; 64 (1) : 129-31.
45. MASTERS CL, SIMMS G, WEINMAN NA et al. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci USA 1985 ; 82 (12) : 4245-9.
46. McKEITH I, DEL SER T, SPANO P et al. Efficacy of rivastigmine in dementia with Lewy bodies : a randomised, double-blind, placebo-controlled international study. Lancet 2000 ; 356 (9247) : 2031-6.
47. MEDA L, CASSATELLA MA, SZENDREI GI et al. Activation of microglial cells by beta-amyloid protein and interferon-gamma. Nature 1995 ; 374 (6523) : 647-50.
48. MILLER BC, ECKMAN EA, SAMBAMURTI K et al. Amyloid-beta peptide levels in brain are inversely correlated with insulysin activity levels in vivo. Proc Natl Acad Sci USA 2003 ; 100 (10) : 6221-6.
49. MULLAN M, CRAWFORD F, AXELMAN K et al. A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of beta-amyloid. Nat Genet 1992 ; 5 : 345-7.
50. NASLUND J, HAROUTUNIAN V, MOHS R et al. Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA 2000 ; 283 (12) : 1571-7.
51. ORGOZO JM, GILMAN S, DARTIGUES JF et al. Subacute meningoencephalitis in asubset of patients with AD after A beta 42 immunization. Neurology 2003 ; 61 : 46-54.
52. PETERSEN R, GRUNDMAN M, THOMAS R et al. Donepezil and vitamin E as treatments for mild cognitive impairment [abstract]. Presented at : Ninth International Conference on Alzheimer's Disease and Related Disorders ; July 17-22, 2004 ; Philadelphia, Pa.
53. QU B, ROSENBERG RN, LI L et al. Gene vaccination to bias the immune response to amyloid-beta peptide as therapy for Alzheimer disease. Arch Neurol 2004 ; 61 (12) : 1859-64.
54. RAMAROSON H, HELMER C, BARBERGER-GATEAU P et al. Prevalence of dementia and Alzheimer's disease among subjects aged 75 years or over : updated results of the PAQUID cohort. Rev Neurol (Paris) 2003 ; 159 (4) : 405-11.
55. REISBERG B, DOODY R, STOFFLER A et al. Memantine Study Group. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 2003 ; 348 (14) : 1333-41.
56. RITCHIE CW, BUSH AI, MACKINNON A et al. Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease : a pilot phase 2 clinical trial. Arch Neurol 2003 ; 60 (12) : 1685-91.
57. ROSENBERG RN, BASKIN F, FOSMIRE JA et al. Altered amyloid protein processing in platelets of patients with Alzheimer disease. Arch Neurol 1997 ; 54 (2) : 139-44.
58. ROSENBERG RN. The molecular and genetic basis of AD : the end of the beginning : the 2000 Wartenberg lecture. Neurology 2000 ; 54 (11) : 2045-54.
59. ROSENBERG RN. Genomic neurology : a new beginning. Arch Neurol 2001 ; 58 (11) : 1739-41.
60. ROSENBERG RN. Translational research on the way to effective therapy for Alzheimer disease. Arch Gen Psychitry 2005 ; 62 : 1186-92.
61. SANO M, ERNESTO C, THOMAS RG et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N Engl J Med 1997; 336 (17) : 1216-22.
62. SAUNDERS AM, STRITTMATTER WJ, SCHMECHEL D et al. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology 1993 ; 43 (8) : 1467-72.
63. SCHENK D, BARBOUR R, DUNN W et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999 ; 400 (6740) : 173-7.
64. SCHONBERGER SJ, EDGAR PF, KYDD R et al. Proteomic analysis of the brain in Alzheimer's disease : molecular phenotype of a complex disease process. Proteomics 2001 ; 1 (12) : 1519-28.
65. SELKOE DJ. Molecular pathology of Alzheimer's disease : the role of amyloid. In : Growdon JH, Rossor MN, eds. Blue Books of Practical Neurology : The Dementias. London, England : Butterworth-Heinemann, Inc. 1998 : 257-83.
66. SELKOE DJ. Alzheimer's disease : genotypes, phenotypes, and treatments. Science 1997 ; 275 (5300) : 630-1.
67. SHEPHERD J, BLAUW GJ, MURPHY MB et al. Prospective Study of Pravastatin in the Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease (Prosper) : a randomised controlled trial. Lancet, 360 (9346) : 1623-30.
68. SHERRINGTON R, ROGAEV EI, LIANG Y et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 1995 ; 375 (6534) : 754-60.
69. SHUMAKER SA, LEGAULT C, KULLER L et al. Women's Health Initiative Memory Study. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in post-menopausal women : Women's Health Initiative Memory Study. JAMA 2004 ; 291 (24) : 2947-58.
70. SHUMAKER SA, LEGAULT C, RAPP SR et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women : the Women's Health Initiative Memory Study : a randomized controlled trial. JAMA 2003 ; 289 (20) : 2651-62.
71. ST GEORGE-HYSLOP PH, TANZI RE, POLINSKY RJ et al. The genetic defect causing familial Alzheimer's disease maps on chromosome 21. Science 1987 ; 35 (4791) : 885-90.
72. SUBRAMANIAN G, ADAMS MD, VENTER JC et al. Implications of the human genome for understanding human biology and medicine. JAMA 2001 ; 86 (18) : 2296-307.
73. TABET N, BIRKS J, GRIMLEY EVANS J. Vitamin E for Alzheimer's disease. Cochrane Database Syst Rev 2000 ; 4 : CD002854.
74. TANZI RE, GUSELLA JF, WATKINS PC et al. Amyloid beta protein gene : cDNA, mRNA distribution, and genetic linkage near the Alzheimer locus. Science 1987 ; 235 (4791) : 880-4.
75. TANZI RE, KOVACS DM, KIM TW et al. The gene defects responsible for familial Alzheimer's disease. Neurobiol Dis 1996 ; 3 (3) : 159-68.
76. TARIOT PN, FARLOW MR, GROSSBERG GT et al. Memantine Study Group. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donépézil : a randomized controlled trial. JAMA 2004 ; 291 (3) : 317-24.
77. TROMMSDORFF M, GOTTHARDT M, HIESBERGER T et al. Reeler/Disabled-like disruption of neuronal migration in knockout mice lacking the VLDL receptor and ApoE receptor 2. Cell 1999 ; 97 (6) : 689-701.
78. WEINER MF, ROSENBERG RN, SVETLIK D et al. Comparison of Alzheimer's disease in Native Americans and Whites. Int Psychogeriatr 2003; 15 (4) : 367-75.
79. WEINER MF, VEGA G, RISSER RC et al. Apolipoprotein E epsilon 4, other risk factors, and course of Alzheimer's disease. Biol Psychiatry 1999 ; 45 (5) : 633-8.
80. WINBLAD B, KILANDER L, ERIKSSON S et al. Donepezil in patients with severe Alzheimer's disease : double-blind, parallel-group, placebo- controlled study. Lancet 2006 ; 367 (9516) : 1057-65.
81. WOLOZIN B, KELLMAN W, RUOSSEAU P et al. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol 2000 ; 57 (10) : 1439-43.
82. YU G, NISHIMURA M, ARAWAKA S et al. Nicastrin modulates presenilin-mediated notch/glp-1 signal transduction and betaAPP processing. Nature 2000 ; 407 (6800) : 48-54.
83. ZABAR Y, KAWAS C. Epidemiology and clinical genetics of Alzheimer disease. In : Clark CM, Trojanowski JQ, eds. Neurodegenerative Dementias. New York, NY : Mcgraw-Hill ; 2000 : 79-94.
84. ZANDI PP, ANTHONY JC, KHACHATURIAN AS et al. Cache County Study Group. Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements. Arch Neurol 2004 ; 61 (1) : 82-8.